Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Pregnancy and Naltrexone Pharmacotherapy

Jones, Cresta W., MD; Terplan, Mishka, MD, MPH

doi: 10.1097/AOG.0000000000002864
Contents: Opioids: Clinical Conundrums
Buy

A 25-year-old woman, gravida 3 para 2 at 12 weeks of gestation, with two prior cesarean deliveries, presents for prenatal care. She is in treatment for opioid use disorder on extended-release naltrexone injection, with a history of opioid overdose, relapse, and poor treatment adherence on methadone and buprenorphine. She asks, “Is it safe for my baby if I continue on this medication? How will you manage my postoperative pain?”

Naltrexone, an opioid antagonist used for the treatment of opioid use disorder, is not well- studied in pregnancy and may pose challenges for analgesia and anesthesia surrounding delivery.

Department of Obstetrics, Gynecology and Women’s Health, University of Minnesota Medical School, Minneapolis, Minnesota; and Virginia Commonwealth University, Richmond, Virginia.

Corresponding author: Cresta W. Jones, MD, Department of Obstetrics, Gynecology and Women’s Health, University of Minnesota Medical School, 606 24th Avenue, S, #401, Minneapolis, MN 55455; email: jonesc@umn.edu.

Financial Disclosure The authors did not report any potential conflicts of interest.

Each author has indicated that he or she has met the journal's requirements for authorship.

© 2018 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.